NewsDialy
MangoRx IP Holdings, LLC, a former subsidiary of Mangoceuticals, Inc., has entered into agreements for a $2.5 million strategic investment. The company reported receiving the first $1.75 million tranche of the funds.
These transactions occur at the subsidiary level and do not result in the issuance of any Mangoceuticals common stock, warrants, or other securities, thereby leaving the parent company's public capitalization structure unchanged.
Under the subscription agreements, two investors have committed to purchasing an aggregate 25% membership interest in MangoRx IP for the total sum. The initial payment covers a 17.5% post-acquisition membership interest.
The remaining 7.5% interest is tied to a second payment of $750,000, which is due within 60 days of the initial closing or by November 28, 2026, subject to the specific terms of the agreement.
Keep reading